27.7 C
New York
Friday, June 5, 2026

Tag: tablet

newssourceFORcompanyinformationcontent1marketreleases

Ageless Shoulders Releases 2025 Update on Indian Club Shoulder Exercises and At-Home Frozen Shoulder Mobility Program

In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs. 
In this 2025 release, Ageless Shoulders expands its digital shoulder mobility system using traditional Indian club exercises to support joint flexibility, address frozen shoulder limitations, and meet rising search demand for non-surgical, at-home movement programs.

Every second counts: Augmented reality tool helps train Canadians for home fire emergencies

Kidde's “Prepare. Plan. Practice.”, a first-of-its-kind digital simulator, brings fire safety training into the home — no downloads required.

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health

DentScribe Launches GPS – AI-Powered “Guided Production System” Transforming Dental Practice Operations and Revenue Optimization

SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- DentScribe.ai today announced the launch of DentScribe GPS (Guided Production System), a groundbreaking addition to its...

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

-  First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of...

Autohome’s International English Website Launches on June 30 Building an Information Hub for Chinese Automakers Going Global

HONG KONG, July 2, 2025 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the globally leading online destination for automobile...

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

World Padel Network™ Launches: Find and Rate Padel Clubs Worldwide

BARCELONA, Spain, July 1, 2025 /PRNewswire/ -- The World Padel Network™ (WPN) has officially launched, offering padel players a multilingual, international platform to discover, compare,...

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

Health and Wellness Market Size Worth USD 11 Trillion by 2034

The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives. 
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTablet

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers